DocGo's SteadyMD Acquisition Ends 50-State Licensing as a Deployment Barrier

DocGo Eliminates Multi-State Deployment Risk

DocGo's acquisition of SteadyMD adds a 50-state licensed virtual clinician workforce to its mobile care platform, removing the single largest deployment barrier for enterprise telehealth buyers: state-by-state credentialing. For companies operating across multiple states, this consolidates what previously required separate vendor relationships or 6-12 month licensing delays into a single contract. The combined platform routes virtual consultations to mobile care teams when physical intervention is needed, cutting the logistics budget by 20-30% compared to separate telehealth and dispatch contracts.

This matters because telehealth utilization has stabilized at 13-17% of total visits—not growing, but permanent. Enterprises still managing telehealth as a separate channel from physical care are paying twice: once for the video platform, again for the care coordination to get patients into clinics or homes when virtual fails. DocGo's model bundles both, directly competing with Teladoc Health's recent acquisitions of Catapult Health and UpLift, which similarly aim to integrate virtual and physical touchpoints.

DocGo's 563.5% three-year revenue growth positions it as the faster-moving challenger to Teladoc's market dominance. Where Teladoc has scale, DocGo has integration speed. The SteadyMD deal gives it immediate national clinician coverage without building state-by-state—something Teladoc achieved through years of organic growth and acquisitions.

Hims & Hers Adds Diagnostics to Skip Clinic Visits Entirely

Hims & Hers acquired Trybe Labs to layer at-home whole-body biomarker testing into its telehealth platform, enabling diagnosis and treatment without a single clinic visit. The company's MedMatch AI platform now correlates lab results with virtual consultations, personalizing treatment plans based on actual biomarkers rather than patient-reported symptoms. This shifts the buyer calculation: instead of telehealth as triage before in-person care, it becomes the complete care episode.

The economics are straightforward. Each avoided follow-up visit saves $50-100 in patient acquisition and scheduling costs, according to utilization data from similar hybrid models. For chronic care management at scale—100,000+ patients, as seen in competitors like HealthSnap—those savings compound. Hims & Hers, already showing 486% three-year revenue growth, is betting that bundled diagnostic-telehealth contracts will win enterprise deals over volume-based video platforms like Zoom, which holds 36.4% market share in basic telemedicine but lacks the diagnostic layer.

This intensifies competition with ResMed's VirtuOx acquisition for sleep and respiratory diagnostics, and LetsGetChecked's Truepill deal for testing-to-prescription fulfillment. The pattern is clear: telehealth vendors are racing to own the entire care pathway, not just the consultation. For buyers, this means fewer vendors to manage but higher switching costs once deployed.

5G Infrastructure Costs Arrive as a Budget Line Item

The 5G telemedicine platform market reached $4.14 billion in 2026, up from $3.51 billion in 2025—an 18% increase driven by remote patient monitoring and AI diagnostics that require sub-10ms latency. This is not optional infrastructure for enterprises deploying high-bandwidth specialties like radiology or real-time triage. 4G's 100ms+ latency makes these use cases unreliable; 5G drops it below 10ms, enabling diagnostics that were previously clinic-only.

HealthSnap's chronic care platform, serving 180+ organizations and 100,000+ patients across 33 states, demonstrates the scale where this matters. At that volume, latency-induced failures—dropped connections, degraded video during critical assessments—create liability exposure and patient dissatisfaction that outweighs the infrastructure cost.

Buyers face $1-5 million pilots for 5G-enabled telehealth, but the ROI case is 2-3x faster triage in urgent care scenarios, measured against the cost of delayed treatment or unnecessary ER visits. The risk is vendor lock-in: once you deploy on a 5G-dependent platform, migrating back to 4G-compatible systems is functionally impossible. Legacy platforms like Teladoc must retrofit for 5G or lose enterprise deals in bandwidth-intensive specialties to newer entrants like Roche-backed AI diagnostic tools.

What This Means for Procurement

Three decisions crystallize for enterprise buyers:

First, multi-state operations should evaluate vendors with nationwide clinician networks first, not state-by-state patchworks. The licensing problem is solved—pay for it or keep managing it internally.

Second, budgets are shifting from standalone telehealth to bundled diagnostic-virtual-mobile contracts. If your current vendor cannot connect test results to treatment plans to physical dispatch, you are managing that integration yourself at higher cost.

Third, 5G infrastructure is a capex decision this year, not next. The market is moving to latency-dependent applications—remote monitoring, AI diagnostics, real-time specialist consults—that do not function on 4G. Deferring the upgrade locks you into lower-capability platforms while competitors deploy faster, more reliable care models.